Pyxis Oncology

Pyxis Oncology

Biotechnology, 35 Cambridgepark Dr, Boston, Massachusetts, 02140, United States, 51-200 Employees

pyxisoncology.com

  • twitter
  • LinkedIn

Who is PYXIS ONCOLOGY

Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppressio...

Read More

map
  • 35 Cambridgepark Dr, Boston, Massachusetts, 02140, United States Headquarters: 35 Cambridgepark Dr, Boston, Massachusetts, 02140, United States
  • 2019 Date Founded: 2019
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from PYXIS ONCOLOGY

Pyxis Oncology Org Chart and Mapping

Employees

Donna Regalado

Director, HR Operations

Stan Szpindor

Vice President, R&D Quality

Weitang Chen

Director Data Management

Aming Zhang

Head of Analytical Development and Qc

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Pyxis Oncology

Answer: Pyxis Oncology's headquarters are located at 35 Cambridgepark Dr, Boston, Massachusetts, 02140, United States

Answer: Pyxis Oncology's official website is https://pyxisoncology.com

Answer: Pyxis Oncology's revenue is $10 Million to $25 Million

Answer: Pyxis Oncology's SIC: 2834

Answer: Pyxis Oncology's NAICS: 325412

Answer: Pyxis Oncology has 51-200 employees

Answer: Pyxis Oncology is in Biotechnology

Answer: Pyxis Oncology contact info: Phone number: Website: https://pyxisoncology.com

Answer: Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies have the potential to address difficult-to-treat cancers and improve patient outcomes.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access